Kailera Therapeutics (NASDAQ:KLRA) Shares Up 7.1% – What’s Next?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) shares were up 7.1% on Tuesday. The company traded as high as $14.89 and last traded at $14.67. Approximately 680,169 shares changed hands during trading, a decline of 23% from the average daily volume of 884,994 shares. The stock had previously closed at $13.70.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on KLRA. Weiss Ratings raised shares of Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. Canaccord Genuity Group initiated coverage on shares of Kailera Therapeutics in a research note on Monday. They issued a “buy” rating and a $44.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kailera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $43.00.

Kailera Therapeutics Price Performance

The stock has a 50 day simple moving average of $12.73 and a two-hundred day simple moving average of $17.65. The company has a market cap of $1.88 billion and a price-to-earnings ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last issued its earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.81. As a group, research analysts forecast that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Hedge funds have recently modified their holdings of the company. Cibc World Market Inc. increased its position in Kailera Therapeutics by 4.8% during the third quarter. Cibc World Market Inc. now owns 37,181 shares of the company’s stock worth $425,000 after purchasing an additional 1,705 shares during the last quarter. Aberdeen Group plc boosted its holdings in Kailera Therapeutics by 209.0% in the 3rd quarter. Aberdeen Group plc now owns 432,661 shares of the company’s stock valued at $4,941,000 after purchasing an additional 292,661 shares during the last quarter. Alps Advisors Inc. grew its stake in shares of Kailera Therapeutics by 31.1% in the 3rd quarter. Alps Advisors Inc. now owns 171,739 shares of the company’s stock valued at $1,961,000 after buying an additional 40,739 shares during the period. Commonwealth Equity Services LLC purchased a new stake in shares of Kailera Therapeutics in the 3rd quarter valued at approximately $134,000. Finally, Profund Advisors LLC purchased a new stake in shares of Kailera Therapeutics in the 3rd quarter valued at approximately $216,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals.